User login
Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer
Article Type
Changed
Thu, 12/15/2022 - 18:05
Display Headline
Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer
On February 3, 2015, the US Food and Drug Administration (FDA) approved palbociclib in combination with letrozole for first-line treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. The combination was reviewed and approved 2 months ahead of schedule under the FDA’s breakthrough therapy designation and priority review program. Palbociclib is an oral small molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6, while letrozole is an aromatase inhibitor (AI), a type of endocrine therapy that reduces circulating estrogen levels. The 2 agents were shown to have potentially synergistic tumor growth inhibitory activity in preclinical models of ER-positive breast cancer.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(3)
Page Number
83-86
Legacy Keywords
Palbociclib, letrozole, breast cancer, ER-positive, HER2-negative, f cyclin-dependent kinases, CDK4, CDK6
Sections
Article PDF
Article PDF
On February 3, 2015, the US Food and Drug Administration (FDA) approved palbociclib in combination with letrozole for first-line treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. The combination was reviewed and approved 2 months ahead of schedule under the FDA’s breakthrough therapy designation and priority review program. Palbociclib is an oral small molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6, while letrozole is an aromatase inhibitor (AI), a type of endocrine therapy that reduces circulating estrogen levels. The 2 agents were shown to have potentially synergistic tumor growth inhibitory activity in preclinical models of ER-positive breast cancer.
Click on the PDF icon at the top of this introduction to read the full article.
On February 3, 2015, the US Food and Drug Administration (FDA) approved palbociclib in combination with letrozole for first-line treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. The combination was reviewed and approved 2 months ahead of schedule under the FDA’s breakthrough therapy designation and priority review program. Palbociclib is an oral small molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6, while letrozole is an aromatase inhibitor (AI), a type of endocrine therapy that reduces circulating estrogen levels. The 2 agents were shown to have potentially synergistic tumor growth inhibitory activity in preclinical models of ER-positive breast cancer.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 13(3)
Issue
The Journal of Community and Supportive Oncology - 13(3)
Page Number
83-86
Page Number
83-86
Article Type
Display Headline
Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer
Display Headline
Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer
Legacy Keywords
Palbociclib, letrozole, breast cancer, ER-positive, HER2-negative, f cyclin-dependent kinases, CDK4, CDK6
Legacy Keywords
Palbociclib, letrozole, breast cancer, ER-positive, HER2-negative, f cyclin-dependent kinases, CDK4, CDK6
Sections
Citation Override
JCSO 2015;13:83-86
Disallow All Ads
Alternative CME
Article PDF Media
Document